Ceapro Inc. (CZO.V)
| Previous Close | 0.6600 |
| Open | 0.6600 |
| Bid | 0.6400 x 0 |
| Ask | 0.6600 x 0 |
| Day's Range | 0.6600 - 0.6600 |
| 52 Week Range | 0.5600 - 0.9200 |
| Volume | 10,325 |
| Avg. Volume | 20,934 |
| Market Cap | 51.271M |
| Beta (5Y Monthly) | 1.49 |
| PE Ratio (TTM) | 94.29 |
| EPS (TTM) | 0.0070 |
| Earnings Date | Nov. 25, 2021 - Nov. 29, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Ceapro Inc. to Present at H.C. Wainwright 23rd Annual Global Investment Conference
EDMONTON, Alberta, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced that Gilles Gagnon, President and Chief Executive Officer of Ceapro will present at the virtual H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021. In addition to the presen
- GlobeNewswire
Ceapro Inc. Reports 2021 Second Quarter and Six-Month Financial Results and Operational Highlights
– Company continues to increase R&D activities to advance clinical and preclinical programs – – Second quarter sales of $4,409,000 compared to $4,666,000 for second quarter 2020 – – Cash generated from operations of $2,128,000 in Q2 2021 compared to $2,195,000 in Q2 2020 – – Maintained production operations during COVID-19 pandemic, providing customers with essential products while ensuring the health and safety of our employees – EDMONTON, Alberta, Aug. 26, 2021 (GLOBE NEWSWIRE) -- Ceapro Inc.
- GlobeNewswire
Ceapro Inc. Enters into Research Collaboration with the Angiogenesis Foundation for Beta Glucan and Avenanthramides
– Research focused on addressing root cause of disease and tissue damage for diseases such as COVID-19 – – Leveraging the unique expertise and methods developed by the Angiogenesis Foundation to conduct pre-clinical studies to characterize the in vivo bioactivity of Ceapro’s oat-derived bioactive products on angiogenesis, wound healing and tissue regeneration – EDMONTON, Alberta, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage
